A phase I/II study of THR-687 for diabetic retinopathy
Phase of Trial: Phase I/II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs THR 687 (Primary)
- Indications Diabetic retinopathy
- Focus Adverse reactions; Therapeutic Use
- 07 Sep 2017 According to a ThromboGenics media release, this company expects to initiate this study in the first half of 2018.
- 21 Mar 2017 New trial record
- 16 Mar 2017 According to a ThromboGenics media release, the company plans to start this study around end of 2017.